drugset / Trial / NCT03299426

Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi

NCT03299426

RandomizedParallel-groupTriple-blindPrevention

Summary

This study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years. Participants will be randomized in a 1:1 ration to receive the study vaccine or the control vaccine (meningococcal group A conjugate vaccine - MCV-A).

Timeline

Start
2018-02-21
Primary completion
2025-01-30
Completion
2027-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meningococcal A Conjugate Vaccine Vaccine 5 ug Intramuscular
Comparator Meningococcal A Conjugate Vaccine Vaccine 10 ug Intramuscular
Subject Typbar-TCV Vaccine 0.5 ml Intramuscular

Indications